NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRK shares have increased by 0.2% and is now trading at $79.42. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Tuesday, April, 28th. The company reported $1.50 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.16. The business had revenue of $12.06 billion for the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The company's revenue was up 11.5% compared to the same quarter last year. During the same period last year, the business posted $1.22 earnings per share. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 26th. Stockholders of record on Monday, June 15th will be given a dividend of $0.61 per share on Tuesday, July 7th. This represents a $2.44 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend is Friday, June 12th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its Board of Directors has authorized a share repurchase plan on Thursday, October 25th 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 5.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

Merck & Co., Inc. issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, April, 28th. The company provided EPS guidance of 5.17-5.37 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.56. The company issued revenue guidance of $46.1-48.1 billion, compared to the consensus revenue estimate of $48.72 billion.

13 brokerages have issued 12-month price targets for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.15 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

Media headlines about MRK stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 14,560,000 shares, a drop of 7.9% from the June 15th total of 15,810,000 shares. Based on an average trading volume of 11,610,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.6% of the company's stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.10%), MERIAN GLOBAL INVESTORS UK Ltd (0.05%), Factory Mutual Insurance Co. (0.05%), Gateway Investment Advisers LLC (0.04%), Manning & Napier Group LLC (0.03%) and Hexavest Inc. (0.03%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Hexavest Inc., Gateway Investment Advisers LLC, Cacti Asset Management LLC, Centre Asset Management LLC, IFM Investors Pty Ltd, HNP Capital LLC, and Exane Derivatives. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks. View insider buying and selling activity for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, Canandaigua National Corp, DNB Asset Management AS, Howe & Rusling Inc., Whittier Trust Co., Fulton Bank N. A., and Legacy Private Trust Co.. View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $79.42.

Merck & Co., Inc. has a market capitalization of $200.46 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]